Drug name - Daklinza
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9421192 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Aug, 2027
(4 years from now) | |
| US8642025 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Aug, 2027
(4 years from now) | |
| US8329159 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Jul, 2029
(6 years from now) | |
| US8629171 | BRISTOL-MYERS SQUIBB | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
Jun, 2031
(8 years from now) | |
| CN101778840A | BRISTOL-MYERS SQUIBB | Crystalline Form Of Methyl ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((Methoxycarbonyl)Amino)-3-Methylbutanoyl)-2-Pyrrolidinyl)-1H-Imidazol-5-Yl)-4-Biphenylyl)-1H-Imidazol-2-Yl)-1-Pyrrolidinyl)Carbonyl)-2-Methylpropyl)Carbamate Dihydrochloride Salt |
Jul, 2021
(1 year, 2 months ago) | |
| CN101778840B | BRISTOL-MYERS SQUIBB | Crystalline Form Of Methyl ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((Methoxycarbonyl)Amino)-3-Methylbutanoyl)-2-Pyrrolidinyl)-1H-Imidazol-5-Yl)-4-Biphenylyl)-1H-Imidazol-2-Yl)-1-Pyrrolidinyl)Carbonyl)-2-Methylpropyl)Carbamate Dihydrochloride Salt |
Jul, 2021
(1 year, 2 months ago) | |
| CN104447707B | BRISTOL-MYERS SQUIBB | Hepatitis C Virus Inhibitors |
Aug, 2027
(4 years from now) | |
| CN104447707A | BRISTOL-MYERS SQUIBB | Hepatitis C Virus Inhibitors |
Aug, 2027
(4 years from now) | |
| CN101558059A | BRISTOL-MYERS SQUIBB | Hepatitis C Virus Inhibitors |
Aug, 2027
(4 years from now) | |
| CN101558059B | BRISTOL-MYERS SQUIBB | Hepatitis C Virus Inhibitor |
Aug, 2027
(4 years from now) | |
| EP2784075A1 | BRISTOL-MYERS SQUIBB | Hepatitis C Virus Inhibitors |
Aug, 2027
(4 years from now) | |
| EP3042901B1 | BRISTOL-MYERS SQUIBB | Hepatitis C Virus Inhibitors |
Aug, 2027
(4 years from now) | |
| EP2784075B1 | BRISTOL-MYERS SQUIBB | Hepatitis C Virus Inhibitors |
Aug, 2027
(4 years from now) | |
| EP3042901A1 | BRISTOL-MYERS SQUIBB | Hepatitis C Virus Inhibitors |
Aug, 2027
(4 years from now) | |
| EP2183244A1 | BRISTOL-MYERS SQUIBB | Crystalline Form Of Methyl ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((Methoxycarbonyl)Amino)-3-Methylbutanoyl)-2-Pyrrolidinyl)-1H-Imidazol-5-Yl)-4-Biphenylyl)-1H-Imidazol-2-Yl)-1-Pyrrolidinyl)Carbonyl)-2-Methylpropyl)Carbamate Dihydrochloride Salt |
Jul, 2028
(5 years from now) | |
| EP2183244B1 | BRISTOL-MYERS SQUIBB | Crystalline Form Of Methyl ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((Methoxycarbonyl)Amino)-3-Methylbutanoyl)-2-Pyrrolidinyl)-1H-Imidazol-5-Yl)-4-Biphenylyl)-1H-Imidazol-2-Yl)-1-Pyrrolidinyl)Carbonyl)-2-Methylpropyl)Carbamate Dihydrochloride Salt |
Jul, 2028
(5 years from now) | |
| EP2049522A2 | BRISTOL-MYERS SQUIBB | Hepatitis C Virus Inhibitors |
Aug, 2029
(6 years from now) | |
| EP2049522B1 | BRISTOL-MYERS SQUIBB | Hepatitis C Virus Inhibitors |
Aug, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8900566 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Aug, 2027
(4 years from now) | |
Drugs and Companies using DACLATASVIR DIHYDROCHLORIDE ingredient
Treatment: Method of inhibiting hepatitis c virus with daklinza and at least one additional compound having anti-hcv activity; method of inhibiting hepatitis c virus
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 30MG BASE | TABLET;ORAL | Discontinued |
| EQ 60MG BASE | TABLET;ORAL | Discontinued |
| EQ 90MG BASE | TABLET;ORAL | Discontinued |
availability in other generic markets.
Click on the highlighted region to filter.